PD-1 aborts the activation trajectory of autoreactive CD8+ T cells to prohibit their acquisition of effector functions

Anti-PD-1 therapy can induce eradication of tumors and immune-related adverse events (irAEs) in humans and model animals. However, how anti-PD-1 therapy modifies cellular phenotypes of CD8(+) T cells to destroy tumors and damage self-tissues remains to be clarified. Here we performed single cell mRNA expression profiling of autoreactive CD8(+) T cells under or beyond PD-1 suppression in target tissues and reconstructed their activation trajectory. Autoreactive CD8(+) T cells went through four activation phases and PD-1 strongly attenuated the transition from the second- to the third-phase, where effector functions were acquired. Shifts in cluster composition of autoreactive CD8(+) T cells markedly reflected the severity of autoimmunity. In addition, genes upregulated along the activation-trajectory in autoimmunity were highly expressed in responders of melanoma patients in anti-PD-1 therapy, suggesting that tumor-specific T cells need to be activated in a similar trajectory to destroy tumors in human patients upon PD-1 blockade. These findings reveal that PD-1 blockade facilitates the activation trajectory of CD8(+) T cells to boost their effector functions. Targeted manipulation of the trajectory could lead to new therapeutic opportunities.